JP2018515572A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515572A5 JP2018515572A5 JP2017560759A JP2017560759A JP2018515572A5 JP 2018515572 A5 JP2018515572 A5 JP 2018515572A5 JP 2017560759 A JP2017560759 A JP 2017560759A JP 2017560759 A JP2017560759 A JP 2017560759A JP 2018515572 A5 JP2018515572 A5 JP 2018515572A5
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- oxo
- dihydro
- benzoxazin
- propanoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 230000001154 acute effect Effects 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 4
- 208000033626 Renal failure acute Diseases 0.000 claims 4
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 4
- 201000011040 acute kidney failure Diseases 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- -1 5-methylpyridin-2-yl Chemical group 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000000197 Acute Cholecystitis Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 102000014461 Ataxins Human genes 0.000 claims 2
- 108010078286 Ataxins Proteins 0.000 claims 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 2
- 206010008614 Cholecystitis acute Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 201000003229 acute pancreatitis Diseases 0.000 claims 2
- 208000012998 acute renal failure Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 201000001352 cholecystitis Diseases 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000023569 ischemic bowel disease Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 235000019260 propionic acid Nutrition 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- GOBGKJNCQBHBRY-UHFFFAOYSA-N 3-[6-chloro-3-oxo-7-(1-pyridazin-3-ylethoxy)-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC(=O)O)C=1)OC(C)C=1N=NC=CC=1 GOBGKJNCQBHBRY-UHFFFAOYSA-N 0.000 claims 1
- JYTPVUAZBZXTKD-UHFFFAOYSA-N 3-[6-chloro-3-oxo-7-(1-pyridazin-3-ylpropoxy)-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC(=O)O)C=1)OC(CC)C=1N=NC=CC=1 JYTPVUAZBZXTKD-UHFFFAOYSA-N 0.000 claims 1
- RSVWNJABIVFJRR-UHFFFAOYSA-N 3-[6-chloro-3-oxo-7-(1-pyridin-2-ylethoxy)-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC(=O)O)C=1)OC(C)C1=NC=CC=C1 RSVWNJABIVFJRR-UHFFFAOYSA-N 0.000 claims 1
- RSNDNGAVHUHAQT-UHFFFAOYSA-N 3-[6-chloro-3-oxo-7-(1-pyridin-2-ylpropoxy)-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC(=O)O)C=1)OC(CC)C1=NC=CC=C1 RSNDNGAVHUHAQT-UHFFFAOYSA-N 0.000 claims 1
- RJMMQGZPOLGVOS-UHFFFAOYSA-N 3-[6-chloro-3-oxo-7-(1-pyrimidin-2-ylethoxy)-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC(=O)O)C=1)OC(C)C1=NC=CC=N1 RJMMQGZPOLGVOS-UHFFFAOYSA-N 0.000 claims 1
- OJDIONFJJMJZHC-UHFFFAOYSA-N 3-[6-chloro-3-oxo-7-(1-pyrimidin-2-ylpropoxy)-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC(=O)O)C=1)OC(CC)C1=NC=CC=N1 OJDIONFJJMJZHC-UHFFFAOYSA-N 0.000 claims 1
- SWSDRDZLVLMIEC-UHFFFAOYSA-N 3-[6-chloro-3-oxo-7-(pyridin-2-ylmethoxy)-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC(=O)O)C=1)OCC1=NC=CC=C1 SWSDRDZLVLMIEC-UHFFFAOYSA-N 0.000 claims 1
- MGCKJMNLYXJDRR-UHFFFAOYSA-N 3-[6-chloro-7-[(5-chloropyridin-2-yl)methoxy]-3-oxo-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC(=O)O)C=1)OCC1=NC=C(C=C1)Cl MGCKJMNLYXJDRR-UHFFFAOYSA-N 0.000 claims 1
- LFQJHCUCBMYSQN-UHFFFAOYSA-N 3-[6-chloro-7-[(5-methylpyridin-2-yl)methoxy]-3-oxo-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC(=O)O)C=1)OCC1=NC=C(C=C1)C LFQJHCUCBMYSQN-UHFFFAOYSA-N 0.000 claims 1
- MWGOKLSBOROOGV-UHFFFAOYSA-N 3-[6-chloro-7-[(6-methylpyridazin-3-yl)methoxy]-3-oxo-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC(=O)O)C=1)OCC=1N=NC(=CC=1)C MWGOKLSBOROOGV-UHFFFAOYSA-N 0.000 claims 1
- CZXSKFMRSYTGRY-UHFFFAOYSA-N 3-[6-chloro-7-[1-(1H-imidazol-2-yl)ethoxy]-3-oxo-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC(=O)O)C=1)OC(C)C=1NC=CN=1 CZXSKFMRSYTGRY-UHFFFAOYSA-N 0.000 claims 1
- JOLQQVFVWYTGEO-UHFFFAOYSA-N 3-[6-chloro-7-[1-(2-methyl-1,3-oxazol-5-yl)ethoxy]-3-oxo-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC(=O)O)C=1)OC(C)C1=CN=C(O1)C JOLQQVFVWYTGEO-UHFFFAOYSA-N 0.000 claims 1
- WCGKETCRFTTYDC-UHFFFAOYSA-N 3-[6-chloro-7-[1-(5-chloropyridin-2-yl)ethoxy]-3-oxo-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC(=O)O)C=1)OC(C)C1=NC=C(C=C1)Cl WCGKETCRFTTYDC-UHFFFAOYSA-N 0.000 claims 1
- VZGKUUTXMQAVBE-UHFFFAOYSA-N 3-[6-chloro-7-[1-(5-chloropyridin-2-yl)propoxy]-3-oxo-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC1=CC2=C(OCC(N2CCC(=O)O)=O)C=C1OC(CC)C1=NC=C(C=C1)Cl VZGKUUTXMQAVBE-UHFFFAOYSA-N 0.000 claims 1
- QLBWXRAKCAMPGI-UHFFFAOYSA-N 3-[6-chloro-7-[1-(5-chloropyrimidin-2-yl)propoxy]-3-oxo-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC(=O)O)C=1)OC(CC)C1=NC=C(C=N1)Cl QLBWXRAKCAMPGI-UHFFFAOYSA-N 0.000 claims 1
- WNTQZBBKHGFDBK-UHFFFAOYSA-N 3-[6-chloro-7-[1-(5-ethylpyridin-2-yl)ethoxy]-3-oxo-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC(=O)O)C=1)OC(C)C1=NC=C(C=C1)CC WNTQZBBKHGFDBK-UHFFFAOYSA-N 0.000 claims 1
- YPEKIBJPRFUIII-UHFFFAOYSA-N 3-[6-chloro-7-[1-(5-fluoropyridin-2-yl)ethoxy]-3-oxo-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC(=O)O)C=1)OC(C)C1=NC=C(C=C1)F YPEKIBJPRFUIII-UHFFFAOYSA-N 0.000 claims 1
- FOFGQLRDQHNTNM-UHFFFAOYSA-N 3-[6-chloro-7-[1-(5-methylpyridin-2-yl)propoxy]-3-oxo-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC(=O)O)C=1)OC(CC)C1=NC=C(C=C1)C FOFGQLRDQHNTNM-UHFFFAOYSA-N 0.000 claims 1
- YFSWASFDCTYXGL-UHFFFAOYSA-N 3-[6-chloro-7-[1-(5-methylpyrimidin-2-yl)propoxy]-3-oxo-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC(=O)O)C=1)OC(CC)C1=NC=C(C=N1)C YFSWASFDCTYXGL-UHFFFAOYSA-N 0.000 claims 1
- KHXOAMVYRBLAJU-UHFFFAOYSA-N 3-[6-chloro-7-[1-(6-methylpyridazin-3-yl)ethoxy]-3-oxo-1,4-benzoxazin-4-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC(=O)O)C=1)OC(C)C=1N=NC(=CC=1)C KHXOAMVYRBLAJU-UHFFFAOYSA-N 0.000 claims 1
- JHDNAOARPUXWSI-UHFFFAOYSA-N ClC=1C(=CC2=C(N(C(CO2)=O)CCC)C1)OC(C)C=1OC=CN1 Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC)C1)OC(C)C=1OC=CN1 JHDNAOARPUXWSI-UHFFFAOYSA-N 0.000 claims 1
- PYSXJNQMHVVHEC-UHFFFAOYSA-N ClC=1C(=CC2=C(N(C(CO2)=O)CCC)C1)OC(CC)C=1N=NC(=CC1)C Chemical compound ClC=1C(=CC2=C(N(C(CO2)=O)CCC)C1)OC(CC)C=1N=NC(=CC1)C PYSXJNQMHVVHEC-UHFFFAOYSA-N 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1508864.4 | 2015-05-22 | ||
| GBGB1508864.4A GB201508864D0 (en) | 2015-05-22 | 2015-05-22 | Compounds |
| PCT/EP2016/061173 WO2016188827A1 (en) | 2015-05-22 | 2016-05-19 | 3-(6-chloro-3-oxo-3,4-dihydro-(2h)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as kmo inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515572A JP2018515572A (ja) | 2018-06-14 |
| JP2018515572A5 true JP2018515572A5 (cg-RX-API-DMAC7.html) | 2019-06-20 |
| JP6728239B2 JP6728239B2 (ja) | 2020-07-22 |
Family
ID=53506233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560759A Active JP6728239B2 (ja) | 2015-05-22 | 2016-05-19 | ３−（６−クロロ−３−オキソ−３，４−ジヒドロ−（２ｈ）−１，４−ベンゾキサジン−４−イル）プロパン酸誘導体、およびその、ｋｍｏ阻害剤としての使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10246447B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3298009B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6728239B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102648283B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107646034B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016266548B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2986609C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2776462T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201508864D0 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2746001C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016188827A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100486099B1 (ko) * | 2002-07-12 | 2005-04-29 | 진금수 | 히트 펌프 시스템 |
| KR100486096B1 (ko) * | 2002-07-12 | 2005-04-29 | 진금수 | 히트 펌프 시스템 |
| GB2568549A (en) * | 2017-11-21 | 2019-05-22 | Univ Leicester | New compounds and uses |
| CN113166781A (zh) | 2018-10-15 | 2021-07-23 | 沃雅戈治疗公司 | 在杆状病毒/Sf9系统中大规模生产rAAV的表达载体 |
| US20260085328A1 (en) | 2022-09-08 | 2026-03-26 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9522615D0 (en) * | 1995-11-03 | 1996-01-03 | Pharmacia Spa | 4-Phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity |
| JPH11180966A (ja) * | 1997-09-09 | 1999-07-06 | Sankyo Co Ltd | アゾール誘導体 |
| SE9904652D0 (sv) * | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
| US6750215B2 (en) * | 2001-08-08 | 2004-06-15 | Pharmacia & Upjohn, S.P.A. | Substituted benzoxazines as integrin antagonists |
| EP1424333A1 (en) | 2002-11-28 | 2004-06-02 | Newron Pharmaceuticals S.p.A. | Halothenoyl-cyclopropane-1-carboxylic acid derivatives |
| EP1475385A1 (en) | 2003-05-05 | 2004-11-10 | Newron Pharmaceuticals S.p.A. | Glycoside derivatives of 2-(3,4-dichlorobenzoyl)-cycopropane-1-carboxylic acid |
| FR2881138B1 (fr) * | 2005-01-27 | 2007-03-02 | Servier Lab | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP1985297A1 (en) * | 2006-01-27 | 2008-10-29 | Japan Tobacco, Inc. | Carboxylic acid compound and use thereof |
| EP2054056A4 (en) | 2006-08-16 | 2010-08-25 | J David Gladstone Inst A Testa | SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE |
| DK2054397T3 (en) | 2006-08-16 | 2016-01-18 | J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone | SMALL MOLECULAR INHIBITORS OF KYNURENIN-3-MONOOXYGENASE |
| WO2010011302A1 (en) | 2008-07-22 | 2010-01-28 | Chdi, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| JP5693452B2 (ja) | 2008-08-04 | 2015-04-01 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | 特定のキヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物およびそれらの使用方法 |
| US8691824B2 (en) | 2008-08-04 | 2014-04-08 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| NZ595263A (en) * | 2009-02-26 | 2013-06-28 | Compositions, synthesis, and methods of utilizing arylpiperazine derivatives | |
| CA2787365A1 (en) | 2010-01-25 | 2011-07-28 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| JP2013030505A (ja) | 2011-07-26 | 2013-02-07 | Sumitomo Electric Ind Ltd | Ｉｉｉ族窒化物半導体レーザ素子 |
| MX2014001088A (es) | 2011-07-28 | 2015-03-19 | Chdi Foundation Inc | Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas. |
| KR20140072037A (ko) * | 2011-08-30 | 2014-06-12 | 씨에이치디아이 파운데이션, 인코포레이티드 | 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법 |
| KR20150000882A (ko) | 2012-04-05 | 2015-01-05 | 씨에이치디아이 파운데이션, 인코포레이티드 | 키뉴레닌-3-모노산소첨가효소 억제제들, 약학 조성물들 및 이의 사용 방법 |
| GB201322512D0 (en) * | 2013-12-19 | 2014-02-05 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
-
2015
- 2015-05-22 GB GBGB1508864.4A patent/GB201508864D0/en not_active Ceased
-
2016
- 2016-05-19 RU RU2017145086A patent/RU2746001C2/ru active
- 2016-05-19 EP EP16723363.4A patent/EP3298009B1/en active Active
- 2016-05-19 CN CN201680029477.XA patent/CN107646034B/zh active Active
- 2016-05-19 CA CA2986609A patent/CA2986609C/en active Active
- 2016-05-19 JP JP2017560759A patent/JP6728239B2/ja active Active
- 2016-05-19 ES ES16723363T patent/ES2776462T3/es active Active
- 2016-05-19 AU AU2016266548A patent/AU2016266548B2/en active Active
- 2016-05-19 WO PCT/EP2016/061173 patent/WO2016188827A1/en not_active Ceased
- 2016-05-19 US US15/574,947 patent/US10246447B2/en active Active
- 2016-05-19 KR KR1020177033325A patent/KR102648283B1/ko active Active
-
2019
- 2019-02-08 US US16/271,332 patent/US10611756B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515572A5 (cg-RX-API-DMAC7.html) | ||
| RU2017145086A (ru) | Производные 3-(6-хлор-3-оксо-3,4-дигидро-(2h)-1,4-бензоксазин-4-ил)пропионовой кислоты и их применение в качестве ингибиторов kmo | |
| US8440672B2 (en) | Diphenyl substituted alkanes | |
| JP2013542937A5 (cg-RX-API-DMAC7.html) | ||
| JP2018534326A5 (cg-RX-API-DMAC7.html) | ||
| JP2021504443A5 (cg-RX-API-DMAC7.html) | ||
| JP2015514794A5 (cg-RX-API-DMAC7.html) | ||
| JP2016507551A5 (cg-RX-API-DMAC7.html) | ||
| JP2008543860A5 (cg-RX-API-DMAC7.html) | ||
| JP2012255002A5 (cg-RX-API-DMAC7.html) | ||
| JP2016529306A5 (cg-RX-API-DMAC7.html) | ||
| CN106456639A (zh) | Hiv逆转录酶抑制剂的前药 | |
| JP2017501174A5 (cg-RX-API-DMAC7.html) | ||
| TW200927133A (en) | Novel 6-pyrimidinyl-pyrimid-2-one derivative | |
| JP2018507223A5 (cg-RX-API-DMAC7.html) | ||
| JP2017519760A5 (cg-RX-API-DMAC7.html) | ||
| JP2010517991A5 (cg-RX-API-DMAC7.html) | ||
| JP2008524211A5 (cg-RX-API-DMAC7.html) | ||
| AU2015367396B2 (en) | 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors | |
| JP2018510192A5 (cg-RX-API-DMAC7.html) | ||
| RU2017145083A (ru) | Производные 3-(5-хлор-2-оксо-2,3-дигидро-1,3-бензотиазол-3-ил)пропановой кислоты и их применение в качестве ингибиторов кмо | |
| JP2008222648A (ja) | ２−置換−５−（ピラゾロピリジン−３−イル）ピラゾロン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤 | |
| BR112017025052B1 (pt) | Composto derivado de ácido 3-(6-cloro-3-oxo-3,4-di-hidro-(2h)-1,4-benzotiazol-4-il) propanóico, uso do mesmo como inibidor de kmo e composição farmacêutica que compreende o referido composto |